Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease

por Crowe, J. Scott, Roberts, Kevin J., Carlton, Timothy M., Maggiore, Luana, Cubitt, Marion F., Clare, Simon, Harcourt, Katherine, Reckless, Jill, MacDonald, Thomas T., Ray, Keith P., Vossenkämper, Anna, West, Michael R.
Publicado 2018

Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease

por Roberts, Kevin J., Cubitt, Marion F., Carlton, Timothy M., Rodrigues-Duarte, Lurdes, Maggiore, Luana, Chai, Ray, Clare, Simon, Harcourt, Katherine, MacDonald, Thomas T., Ray, Keith P., Vossenkämper, Anna, West, Michael R., Crowe, J. Scott
Publicado 2021

Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients

por Nurbhai, Suhail, Roberts, Kevin J., Carlton, Timothy M., Maggiore, Luana, Cubitt, Marion F., Ray, Keith P., Reckless, Jill, Mohammed, Hafeez, Irving, Peter, MacDonald, Thomas T., Vossenkämper, Anna, West, Michael R., Parkes, Gareth C., Crowe, J. Scott
Publicado 2019